Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
CONCLUSIONS: Breast cancer patients treated with adjuvant trastuzumab in the HOP setting had a shorter duration of trastuzumab treatment and fewer trastuzumab infusions but incurred higher monthly total costs than patients treated in the POV setting.
PMID: 24761820 [PubMed - in process]
Source: Journal of Managed Care Pharmacy - Category: Drugs & Pharmacology Tags: J Manag Care Pharm Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Health Management | Herceptin | Hospital Management | Insurance | Managed Care | Medicare | Study